Silver Creek is a clinical-stage biopharmaceutical company with a mission to deliver life-changing medicines to patients in need. Our groundbreaking therapies are designed to target and heal damaged tissues.
Silver Creek is a clinical-stage biopharmaceutical company with a mission to deliver life-changing medicines to patients in need. Our groundbreaking therapies are designed to target and heal damaged tissues.
Our Smart Growth Factor™ technology enables the rapid development of growth factor fusion proteins with broad applicability. Our lead asset is a first-in-class, targeted fusion protein that precisely delivers the cell survival functions of IGF1 to sites of injury.
Our lead asset, scp776, has shown efficacy in preclinical models of stroke, heart attack, and kidney injury. Scp776 is currently under investigation in a Phase II study in stroke patients.
Our lead asset, scp776, has successfully demonstrated proof-of-concept efficacy in a Phase 2a study in acute ischemic stroke. We are currently planning a Phase 2b/3 Registrational program.
Scp776 has shown efficacy in other preclinical acute injury models, including heart attack and kidney injury.
